Contact
searchSearch
HMP Global
Login

Prostate Cancer Specialty Channel

Conference Coverage
First-Line Enzalutamide Plus Ra223 Significantly Improves Radiological PFS in Metastatic Castration-Resistant Prostate Cancer
09/14/2024
Findings from the phase 3 PEACE-3 trial demonstrate the addition of 6 cycles of Ra223 to enzalutamide in the first-line treatment of metastatic castration-resistant prostate cancer significantly improves radiological PFS vs enzalutamide alone.
Findings from the phase 3 PEACE-3 trial demonstrate the addition of 6 cycles of Ra223 to enzalutamide in the first-line treatment of metastatic castration-resistant prostate cancer significantly improves radiological PFS vs enzalutamide alone.
Findings from the phase 3...
09/14/2024
Oncology
News
No Improvement From Adjuvant Radiotherapy Post-Prostatectomy for Patients With Prostate Cancer At Risk of Recurrence
05/14/2024

Stephanie Holland 

Stephanie Holland 
According to long-term results from the RADICALS-RT study, adjuvant radiotherapy does not meaningfully improve disease control and increases the risk of urinary and bowel morbidities among patients with prostate cancer at risk of recurrence...
According to long-term results from the RADICALS-RT study, adjuvant radiotherapy does not meaningfully improve disease control and increases the risk of urinary and bowel morbidities among patients with prostate cancer at risk of recurrence...
According to long-term results...
05/14/2024
Oncology
News
Hypofractionated Radiotherapy as Acceptable Treatment Option Post-Prostatectomy
04/03/2024

Stephanie Holland 

Stephanie Holland 
According to results from the phase 3 NRG-GU003 trial, hypofractionated postprostatectomy radiotherapy did not significantly increase the likeliness of experiencing patient-reported genitourinary or gastrointestinal symptoms 1 to 2 years post...
According to results from the phase 3 NRG-GU003 trial, hypofractionated postprostatectomy radiotherapy did not significantly increase the likeliness of experiencing patient-reported genitourinary or gastrointestinal symptoms 1 to 2 years post...
According to results from the...
04/03/2024
Oncology
News
Intermittent, Intensified Androgen Deprivation Therapy Provided PSA Survival Benefit for Patients With High-Risk Biochemically Relapsed Prostate Cancer
02/23/2024

Allison Casey 

Allison Casey 
According to interim results from a phase 3 study, the addition of apalutamide to androgen deprivation therapy showed a statistically and clinically significant improvement of PSA progression-free survival among patients with high-risk...
According to interim results from a phase 3 study, the addition of apalutamide to androgen deprivation therapy showed a statistically and clinically significant improvement of PSA progression-free survival among patients with high-risk...
According to interim results...
02/23/2024
Oncology
Conference Coverage
Dose-Escalated Radiotherapy Plus Long-Term Androgen-Deprivation Therapy Deemed Safe, Effective for High-Risk Prostate Cancer
01/25/2024
According to a phase 3 trial, dose-escalated radiotherapy combined with long-term androgen deprivation therapy improved the survival outcomes, without increasing toxicities, among patients with high-risk prostate cancer.
According to a phase 3 trial, dose-escalated radiotherapy combined with long-term androgen deprivation therapy improved the survival outcomes, without increasing toxicities, among patients with high-risk prostate cancer.
According to a phase 3 trial,...
01/25/2024
Oncology
Quiz
Improving Detection of Clinically Significant Prostate Cancer
01/15/2024
True or False: Adding the PRIMARY score for patients with Prostate Imaging Reporting and Data System (PI-RADS) 4/5 showed a net benefit in detecting clinically significant prostate cancer.
True or False: Adding the PRIMARY score for patients with Prostate Imaging Reporting and Data System (PI-RADS) 4/5 showed a net benefit in detecting clinically significant prostate cancer.
True or False: Adding the...
01/15/2024
Oncology
News
PRIMARY Score Superior to MRI for Detecting Clinically Significant Prostate Cancer
01/12/2024
In a retrospective cohort study, the PRIMARY score was found to be superior to MRI in detecting clinically significant prostate cancer, demonstrating added diagnostic value in patients with negative or equivocal MRI results.
In a retrospective cohort study, the PRIMARY score was found to be superior to MRI in detecting clinically significant prostate cancer, demonstrating added diagnostic value in patients with negative or equivocal MRI results.
In a retrospective cohort study,...
01/12/2024
Oncology
News
Actinium-255-PSMA Radioligand Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer
01/12/2024
According to a retrospective study, actinium-255-PSMA radioligand therapy showed a substantial antitumor effect among patients with metastatic castration-resistant prostate cancer.
According to a retrospective study, actinium-255-PSMA radioligand therapy showed a substantial antitumor effect among patients with metastatic castration-resistant prostate cancer.
According to a retrospective...
01/12/2024
Oncology
News
Real-World Data Shows Benefit of Triplet Therapy for Patients With Metastatic Hormone-Sensitive Prostate Cancer
01/05/2024
A real world study found triplet therapy to be an effective and tolerable treatment option for patients with metastatic hormone-sensitive prostate cancer.
A real world study found triplet therapy to be an effective and tolerable treatment option for patients with metastatic hormone-sensitive prostate cancer.
A real world study found triplet...
01/05/2024
Oncology
News
Darolutamide Benefit May Have Been Underestimated Among Patients With Non-Metastatic Castration-Resistant Prostate Cancer
12/12/2023
According to sensitivity analyses, the original analysis of the ARAMIS trial may have underestimated the overall survival benefit of darolutamide among patients with non-metastatic castration-resistant prostate cancer.
According to sensitivity analyses, the original analysis of the ARAMIS trial may have underestimated the overall survival benefit of darolutamide among patients with non-metastatic castration-resistant prostate cancer.
According to sensitivity...
12/12/2023
Oncology
News
Olaparib Benefit for Patients With Metastatic Castration-Resistant Prostate and BRCA Alterations Consistent Across Subgroups
12/01/2023
According to an exploratory subgroup analysis from the phase 3 PROfound trial, the rPFS and OS benefit from olaparib for patients with BRCA-altered metastatic castration-resistant prostate cancer was consistent across all subgroups.
According to an exploratory subgroup analysis from the phase 3 PROfound trial, the rPFS and OS benefit from olaparib for patients with BRCA-altered metastatic castration-resistant prostate cancer was consistent across all subgroups.
According to an exploratory...
12/01/2023
Oncology

News

Conference Coverage
First-Line Enzalutamide Plus Ra223 Significantly Improves Radiological PFS in Metastatic Castration-Resistant Prostate Cancer
09/14/2024
Findings from the phase 3 PEACE-3 trial demonstrate the addition of 6 cycles of Ra223 to enzalutamide in the first-line treatment of metastatic castration-resistant prostate cancer significantly improves radiological PFS vs enzalutamide alone.
Findings from the phase 3 PEACE-3 trial demonstrate the addition of 6 cycles of Ra223 to enzalutamide in the first-line treatment of metastatic castration-resistant prostate cancer significantly improves radiological PFS vs enzalutamide alone.
Findings from the phase 3...
09/14/2024
Oncology
News
No Improvement From Adjuvant Radiotherapy Post-Prostatectomy for Patients With Prostate Cancer At Risk of Recurrence
05/14/2024

Stephanie Holland 

Stephanie Holland 
According to long-term results from the RADICALS-RT study, adjuvant radiotherapy does not meaningfully improve disease control and increases the risk of urinary and bowel morbidities among patients with prostate cancer at risk of recurrence...
According to long-term results from the RADICALS-RT study, adjuvant radiotherapy does not meaningfully improve disease control and increases the risk of urinary and bowel morbidities among patients with prostate cancer at risk of recurrence...
According to long-term results...
05/14/2024
Oncology
News
Hypofractionated Radiotherapy as Acceptable Treatment Option Post-Prostatectomy
04/03/2024

Stephanie Holland 

Stephanie Holland 
According to results from the phase 3 NRG-GU003 trial, hypofractionated postprostatectomy radiotherapy did not significantly increase the likeliness of experiencing patient-reported genitourinary or gastrointestinal symptoms 1 to 2 years post...
According to results from the phase 3 NRG-GU003 trial, hypofractionated postprostatectomy radiotherapy did not significantly increase the likeliness of experiencing patient-reported genitourinary or gastrointestinal symptoms 1 to 2 years post...
According to results from the...
04/03/2024
Oncology
News
Intermittent, Intensified Androgen Deprivation Therapy Provided PSA Survival Benefit for Patients With High-Risk Biochemically Relapsed Prostate Cancer
02/23/2024

Allison Casey 

Allison Casey 
According to interim results from a phase 3 study, the addition of apalutamide to androgen deprivation therapy showed a statistically and clinically significant improvement of PSA progression-free survival among patients with high-risk...
According to interim results from a phase 3 study, the addition of apalutamide to androgen deprivation therapy showed a statistically and clinically significant improvement of PSA progression-free survival among patients with high-risk...
According to interim results...
02/23/2024
Oncology
Conference Coverage
Dose-Escalated Radiotherapy Plus Long-Term Androgen-Deprivation Therapy Deemed Safe, Effective for High-Risk Prostate Cancer
01/25/2024
According to a phase 3 trial, dose-escalated radiotherapy combined with long-term androgen deprivation therapy improved the survival outcomes, without increasing toxicities, among patients with high-risk prostate cancer.
According to a phase 3 trial, dose-escalated radiotherapy combined with long-term androgen deprivation therapy improved the survival outcomes, without increasing toxicities, among patients with high-risk prostate cancer.
According to a phase 3 trial,...
01/25/2024
Oncology
News
PRIMARY Score Superior to MRI for Detecting Clinically Significant Prostate Cancer
01/12/2024
In a retrospective cohort study, the PRIMARY score was found to be superior to MRI in detecting clinically significant prostate cancer, demonstrating added diagnostic value in patients with negative or equivocal MRI results.
In a retrospective cohort study, the PRIMARY score was found to be superior to MRI in detecting clinically significant prostate cancer, demonstrating added diagnostic value in patients with negative or equivocal MRI results.
In a retrospective cohort study,...
01/12/2024
Oncology
News
Actinium-255-PSMA Radioligand Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer
01/12/2024
According to a retrospective study, actinium-255-PSMA radioligand therapy showed a substantial antitumor effect among patients with metastatic castration-resistant prostate cancer.
According to a retrospective study, actinium-255-PSMA radioligand therapy showed a substantial antitumor effect among patients with metastatic castration-resistant prostate cancer.
According to a retrospective...
01/12/2024
Oncology
News
Real-World Data Shows Benefit of Triplet Therapy for Patients With Metastatic Hormone-Sensitive Prostate Cancer
01/05/2024
A real world study found triplet therapy to be an effective and tolerable treatment option for patients with metastatic hormone-sensitive prostate cancer.
A real world study found triplet therapy to be an effective and tolerable treatment option for patients with metastatic hormone-sensitive prostate cancer.
A real world study found triplet...
01/05/2024
Oncology
News
Darolutamide Benefit May Have Been Underestimated Among Patients With Non-Metastatic Castration-Resistant Prostate Cancer
12/12/2023
According to sensitivity analyses, the original analysis of the ARAMIS trial may have underestimated the overall survival benefit of darolutamide among patients with non-metastatic castration-resistant prostate cancer.
According to sensitivity analyses, the original analysis of the ARAMIS trial may have underestimated the overall survival benefit of darolutamide among patients with non-metastatic castration-resistant prostate cancer.
According to sensitivity...
12/12/2023
Oncology
News
Olaparib Benefit for Patients With Metastatic Castration-Resistant Prostate and BRCA Alterations Consistent Across Subgroups
12/01/2023
According to an exploratory subgroup analysis from the phase 3 PROfound trial, the rPFS and OS benefit from olaparib for patients with BRCA-altered metastatic castration-resistant prostate cancer was consistent across all subgroups.
According to an exploratory subgroup analysis from the phase 3 PROfound trial, the rPFS and OS benefit from olaparib for patients with BRCA-altered metastatic castration-resistant prostate cancer was consistent across all subgroups.
According to an exploratory...
12/01/2023
Oncology

Interactive Features

Quiz
Improving Detection of Clinically Significant Prostate Cancer
01/15/2024
True or False: Adding the PRIMARY score for patients with Prostate Imaging Reporting and Data System (PI-RADS) 4/5 showed a net benefit in detecting clinically significant prostate cancer.
True or False: Adding the PRIMARY score for patients with Prostate Imaging Reporting and Data System (PI-RADS) 4/5 showed a net benefit in detecting clinically significant prostate cancer.
True or False: Adding the...
01/15/2024
Oncology
Quiz
Adjuvant Radiotherapy Following Radical Prostatectomy
11/13/2023
Test your knowledge on the results from RADICALS RT trial evaluating adjuvant radiotherapy after radical prostatectomy.
Test your knowledge on the results from RADICALS RT trial evaluating adjuvant radiotherapy after radical prostatectomy.
Test your knowledge on the...
11/13/2023
Oncology
Quiz
Biweekly vs Triweekly Cabazitaxel for Patients With Metastatic Castration-Resistant Prostate Cancer
11/10/2023
Test your knowledge with this quiz on the biweekly cabazitaxel regimen used in the phase 3 CASBASTY trial, for patients with metastatic castration-resistant prostate cancer.
Test your knowledge with this quiz on the biweekly cabazitaxel regimen used in the phase 3 CASBASTY trial, for patients with metastatic castration-resistant prostate cancer.
Test your knowledge with this...
11/10/2023
Oncology
Quiz
Adaptive 177Lu-PSMA-617 Dosing in the ENZA-p Trial
11/10/2023
Test your knowledge with this quiz on the adaptive dosing utilized in the ENZA-p trial, evaluating the addition of 177Lu-PSMA-617 to enzalutamide for patients with metastatic castration-resistant prostate cancer.
Test your knowledge with this quiz on the adaptive dosing utilized in the ENZA-p trial, evaluating the addition of 177Lu-PSMA-617 to enzalutamide for patients with metastatic castration-resistant prostate cancer.
Test your knowledge with this...
11/10/2023
Oncology
Quiz
True or False: A study found that the risk of prostate cancer following a transurethral resection of the prostate with a benign histology was higher than the risk for patients with a negative prostate biopsy.
11/02/2022
True or False: A study found that the risk of prostate cancer following a transurethral resection of the prostate with a benign histology was higher than the risk for patients with a negative prostate biopsy.
True or False: A study found that the risk of prostate cancer following a transurethral resection of the prostate with a benign histology was higher than the risk for patients with a negative prostate biopsy.
True or False: A study found...
11/02/2022
Oncology
Quiz
Quiz: Enzalutamide Plus Testosterone Suppression for Metastatic Hormone-Sensitive Prostate Cancer
09/02/2022
In the ENZAMET trial evaluating the addition of enzalutamide to testosterone suppression for patients with metastatic hormone-sensitive prostate cancer, did the extended follow-up find that the benefit from enzalutamide was sustained at the...
In the ENZAMET trial evaluating the addition of enzalutamide to testosterone suppression for patients with metastatic hormone-sensitive prostate cancer, did the extended follow-up find that the benefit from enzalutamide was sustained at the...
In the ENZAMET trial evaluating...
09/02/2022
Oncology
Quiz
Quiz: Does the Polaris Test Prognosticate Risk of Metastasis in Prostate Cancer?
07/21/2022
Quiz: The commercially-available Polaris test was able to prognosticate the risk of metastasis in which patients with prostate cancer?
Quiz: The commercially-available Polaris test was able to prognosticate the risk of metastasis in which patients with prostate cancer?
Quiz: The commercially-available...
07/21/2022
Oncology
Test Your Knowledge
Quiz: Can the Prolaris Test Estimate Metastasis in Prostate Cancer?
09/02/2021
True or false: For patients with intermediate or high-risk prostate cancer, the Prolaris test can provide an extremely precise and accurate risk estimate of metastasis after radiation therapy.
True or false: For patients with intermediate or high-risk prostate cancer, the Prolaris test can provide an extremely precise and accurate risk estimate of metastasis after radiation therapy.
True or false: For patients with...
09/02/2021
Oncology
Test Your Knowledge
Quiz: Can Large Antibodies Target PSMA Expression During mCRPC Treatment?
07/29/2021
True or False: Since small molecule ligands can target PSMA expression, this indicates that large antibodies cannot during mCRPC treatment.
True or False: Since small molecule ligands can target PSMA expression, this indicates that large antibodies cannot during mCRPC treatment.
True or False: Since small...
07/29/2021
Oncology
Test Your Knowledge
Quiz: Which Approach Offers Improved Safety with J591 for mCRPC?
07/29/2021
Which treatment approach demonstrates greater safety outcomes when using a full-length antibody to target PSMA, particularly with actinium J591, for patients with mCRPC?
Which treatment approach demonstrates greater safety outcomes when using a full-length antibody to target PSMA, particularly with actinium J591, for patients with mCRPC?
Which treatment approach...
07/29/2021
Oncology

Recent News

News
No Improvement From Adjuvant Radiotherapy Post-Prostatectomy for Patients With Prostate Cancer At Risk of Recurrence
05/14/2024

Stephanie Holland 

Stephanie Holland 
According to long-term results from the RADICALS-RT study, adjuvant radiotherapy does not meaningfully improve disease control and increases the risk of urinary and bowel morbidities among patients with prostate cancer at risk of recurrence...
According to long-term results from the RADICALS-RT study, adjuvant radiotherapy does not meaningfully improve disease control and increases the risk of urinary and bowel morbidities among patients with prostate cancer at risk of recurrence...
According to long-term results...
05/14/2024
Oncology
News
Hypofractionated Radiotherapy as Acceptable Treatment Option Post-Prostatectomy
04/03/2024

Stephanie Holland 

Stephanie Holland 
According to results from the phase 3 NRG-GU003 trial, hypofractionated postprostatectomy radiotherapy did not significantly increase the likeliness of experiencing patient-reported genitourinary or gastrointestinal symptoms 1 to 2 years post...
According to results from the phase 3 NRG-GU003 trial, hypofractionated postprostatectomy radiotherapy did not significantly increase the likeliness of experiencing patient-reported genitourinary or gastrointestinal symptoms 1 to 2 years post...
According to results from the...
04/03/2024
Oncology
News
Intermittent, Intensified Androgen Deprivation Therapy Provided PSA Survival Benefit for Patients With High-Risk Biochemically Relapsed Prostate Cancer
02/23/2024

Allison Casey 

Allison Casey 
According to interim results from a phase 3 study, the addition of apalutamide to androgen deprivation therapy showed a statistically and clinically significant improvement of PSA progression-free survival among patients with high-risk...
According to interim results from a phase 3 study, the addition of apalutamide to androgen deprivation therapy showed a statistically and clinically significant improvement of PSA progression-free survival among patients with high-risk...
According to interim results...
02/23/2024
Oncology
News
PRIMARY Score Superior to MRI for Detecting Clinically Significant Prostate Cancer
01/12/2024
In a retrospective cohort study, the PRIMARY score was found to be superior to MRI in detecting clinically significant prostate cancer, demonstrating added diagnostic value in patients with negative or equivocal MRI results.
In a retrospective cohort study, the PRIMARY score was found to be superior to MRI in detecting clinically significant prostate cancer, demonstrating added diagnostic value in patients with negative or equivocal MRI results.
In a retrospective cohort study,...
01/12/2024
Oncology
News
Actinium-255-PSMA Radioligand Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer
01/12/2024
According to a retrospective study, actinium-255-PSMA radioligand therapy showed a substantial antitumor effect among patients with metastatic castration-resistant prostate cancer.
According to a retrospective study, actinium-255-PSMA radioligand therapy showed a substantial antitumor effect among patients with metastatic castration-resistant prostate cancer.
According to a retrospective...
01/12/2024
Oncology
News
Real-World Data Shows Benefit of Triplet Therapy for Patients With Metastatic Hormone-Sensitive Prostate Cancer
01/05/2024
A real world study found triplet therapy to be an effective and tolerable treatment option for patients with metastatic hormone-sensitive prostate cancer.
A real world study found triplet therapy to be an effective and tolerable treatment option for patients with metastatic hormone-sensitive prostate cancer.
A real world study found triplet...
01/05/2024
Oncology
News
Darolutamide Benefit May Have Been Underestimated Among Patients With Non-Metastatic Castration-Resistant Prostate Cancer
12/12/2023
According to sensitivity analyses, the original analysis of the ARAMIS trial may have underestimated the overall survival benefit of darolutamide among patients with non-metastatic castration-resistant prostate cancer.
According to sensitivity analyses, the original analysis of the ARAMIS trial may have underestimated the overall survival benefit of darolutamide among patients with non-metastatic castration-resistant prostate cancer.
According to sensitivity...
12/12/2023
Oncology
News
Olaparib Benefit for Patients With Metastatic Castration-Resistant Prostate and BRCA Alterations Consistent Across Subgroups
12/01/2023
According to an exploratory subgroup analysis from the phase 3 PROfound trial, the rPFS and OS benefit from olaparib for patients with BRCA-altered metastatic castration-resistant prostate cancer was consistent across all subgroups.
According to an exploratory subgroup analysis from the phase 3 PROfound trial, the rPFS and OS benefit from olaparib for patients with BRCA-altered metastatic castration-resistant prostate cancer was consistent across all subgroups.
According to an exploratory...
12/01/2023
Oncology
News
255AC-J591 Shows Preliminary Efficacy, Safety Among Patients with Metastatic Castration-Resistant Prostate Cancer
11/30/2023
According to a phase 1 trial, a single dose of 255AC-J591 was safe and showed preliminary efficacy among patients with metastatic castration-resistant prostate cancer.
According to a phase 1 trial, a single dose of 255AC-J591 was safe and showed preliminary efficacy among patients with metastatic castration-resistant prostate cancer.
According to a phase 1 trial, a...
11/30/2023
Oncology
News
Enzalutamide Approved for Non-Metastatic Castration Sensitive Prostate Cancer With Biochemical Recurrence
11/21/2023
On November 17, 2023, the FDA approved enzalutamide for patients with non-metastatic castration sensitive prostate cancer with biochemical recurrence at high risk for metastasis.
On November 17, 2023, the FDA approved enzalutamide for patients with non-metastatic castration sensitive prostate cancer with biochemical recurrence at high risk for metastasis.
On November 17, 2023, the FDA...
11/21/2023
Oncology
News
Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer
11/14/2024
According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.
According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.
According to a retrospective...
11/14/2024
Oncology
News
Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer
11/14/2024
According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.
According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.
According to results from the...
11/14/2024
Oncology
News
Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma
11/13/2024
Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.
Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.
Results from the phase 2...
11/13/2024
Oncology
News
Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas
11/12/2024
According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...
According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...
According to a phase 2b trial,...
11/12/2024
Oncology
News
Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer
11/12/2024
According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.
According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.
According to final results from...
11/12/2024
Oncology
News
Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer
11/11/2024
According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.
According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.
According to results from a...
11/11/2024
Oncology
FDA Approval
FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia
11/08/2024
On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
On November 8, 2024, the FDA...
11/08/2024
Oncology
News
Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer
11/07/2024
While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.
While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.
While naporafenib plus...
11/07/2024
Oncology
News
Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer
11/06/2024
According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.
According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.
According to results from a...
11/06/2024
Oncology
News
Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma
11/05/2024
A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.
A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.
A single-center real-world study...
11/05/2024
Oncology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use